27685-94-5

Basic information

• Product Name: 4-Chlorothieno[3,2-c]pyridine
• Synonyms: 4-CHLOROTHIENO[3,2-C]PYRIDINE;4-Chlorothieno[3,2-c]pyri...;Thieno[3,2-c]pyridine, 4-chloro-
• CAS NO: 27685-94-5
• Molecular Formula: C₇H₄ClNS
• Molecular Weight: 169.63
• Product Categories: Halides;API intermediates;Pyridine;Fused Ring Systems
• Mol File: 27685-94-5.mol
• Article Data: 7

Chemical Properties

• Melting Point: 97-100°C
• Boiling Point: 296.5 °C at 760 mmHg
• Flash Point: 133.118 °C
• Appearance: /
• Density: 1.435 g/cm³
• Vapor Pressure: 0.003mmHg at 25°C
• Refractive Index: 1.696
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• PKA: -0.26±0.30(Predicted)
• CAS DataBase Reference: 4-Chlorothieno[3,2-c]pyridine(CAS DataBase Reference)
• NIST Chemistry Reference: 4-Chlorothieno[3,2-c]pyridine(27685-94-5)
• EPA Substance Registry System: 4-Chlorothieno[3,2-c]pyridine(27685-94-5)

Safety Data

• Hazard Codes: Xi,T
• Statements: 25-36
• Safety Statements: 26-45
• RIDADR: UN 2811 6.1 / PGIII
• WGK Germany: 3
• HazardClass: IRRITANT
• Hazardous Substances Data: 27685-94-5(Hazardous Substances Data)

Usage

General Description

4-Chlorothieno[3,2-c]pyridine is a chemical compound with complex structure belonging to the class of organic compounds known as phenylpiperidines. These are compounds containing a phenylpiperidine skeleton, which consists of a piperidine bound to a phenyl group. While there is not much specifically noted about its properties or uses, compounds of similar types are often used in the chemical and pharmaceutical industries. For instance, the phenylpiperidine class includes such notable drugs as fentanyl, a potent synthetic opioid analgesic. However, the specific uses or properties of 4-Chlorothieno[3,2-c]pyridine are not clearly reported in the general literature.

InChI:InChI=1/C7H4ClNS/c8-7-5-2-4-10-6(5)1-3-9-7/h1-4H

Upstream product

• 27685-92-3 4-oxo-4,5-dihydrothieno[3,2-c]pyridine 
• 88-13-1 3-Thiophene carboxylic acid 

Downstream Products

• 29079-76-3 (3,4-dimethoxy-phenyl)-thieno[3,2-c]pyridin-4-yl-acetonitrile 
• 106261-27-2 4-(1-piperazinyl)thieno<3,2-c>pyridine 
• 85517-58-4 4-(4-Methoxybenzyl)-thieno<3,2-c>pyridin 
• 85517-57-3 4-Benzylthieno<3,2-c>pyridin 
• 27685-92-3 thieno[3,2-c]pyridin-4-ol 
• 215453-35-3 thieno[3,2-c]pyridin-4-amine 
• 215453-36-4 N-(thieno[3,2-c]pyridin-4-yl)benzamide 
• 215453-37-5 N-(2-formylthieno[3,2-c]pyridin-4-yI)benzamide 
• 215453-38-6 N-(2-hydroxymethyl-thieno[3,2-c]pyridin-4-yl)-benzamide 
• 215453-39-7 2-(4-benzoylamino-thieno[3,2-c]pyridin-2-ylmethyl)-2-tert-butoxycarbonylamino-malonic acid diethyl ester 
• 119924-12-8 4-<4-(thieno<3,2-c>pyridin-4-yl)-1-piperazinyl>-1-(4-fluorophenyl)-1-butanone 
• 106260-94-0 α-(4-fluorophenyl)-4-(thieno<3,2-c>pyridin-4-yl)-1-piperazinebutanol 
• 119924-11-7 4-(4-{3-[2-(4-Fluoro-phenyl)-[1,3]dioxolan-2-yl]-propyl}-piperazin-1-yl)-thieno[3,2-c]pyridine 
• 106260-99-5 4-[4-(4-Thieno[3,2-c]pyridin-4-yl-piperazin-1-yl)-butyl]-thiomorpholine-3,5-dione; compound with toluene-4-sulfonic acid 

Relevant articles and documents

Organic metal compound and organic light-emitting device

Organic metal compounds and organic light-emitting devices employing the same are provided. The organic metal compound has a chemical structure of Formula (I) or Formula (II): In particular, one of the following two conditions (1) and (2) is met: (1) R1 is deuterium or C1-6 deuterated alkyl group, when R3 and R4 are independently hydrogen, halogen, C1-6 alkyl group, C1-6 fluoroalkyl or C3-12 heteroaryl group; and (2) R1 is hydrogen, deuterium, C1-6 alkyl group, C1-6 deuterated alkyl group, C3-12 heteroaryl group, or C6-12 aryl group, when at least one of R3 and R4 is C6-12 aryl group or C6-12 fluoroaryl group.

Design and synthesis of piperazinylpyridine derivatives as novel 5-HT 1A agonists/5-HT3 antagonists for the treatment of irritable bowel syndrome (IBS)

We have prepared a series of piperazinylpyridine derivatives for the treatment of irritable bowel syndrome (IBS). These compounds, which were designed by pharmacophore analysis, bind to both serotonin subtype 1A (5-HT 1A) and subtype 3 (5-HT3) receptors. The nitrogen atom of the isoquinoline, a methoxy group and piper-azine were essential to the pharmacophore for binding to these receptors. We also synthesized furo- and thienopyridine derivatives according to structure-activity relationship analyses. Compound 17c (TZB-20810) had high affinities to these receptors and exhibited 5-HT1A agonistic activity and 5-HT3 antagonistic activity concurrently, and is a promising drug for further development in the treatment of IBS.

SUBSTITUTED SULFONIC ACID N-[(AMINOIMINOMETHYL)PHENYLALKYL]-AZAHETEROCYCLAMIDE COMPOUNDS

The compounds of formula I exhibit useful pharmacological activity and accordingly are incorporated into pharmaceutical compositions and used in the treatment of patients suffering from certain medical disorders. More specifically, they are inhibitors of the activity of Factor Xa. The present invention is directed to compounds of formula I, compositions containing compounds of formula I, and their use, which are for treating a patient suffering from, or subject to, physiological condition which can be ameliorated by the administration of an inhibitor of the activity of Factor Xa.